451 related articles for article (PubMed ID: 30139780)
1. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
Bleecker ER; Wechsler ME; FitzGerald JM; Menzies-Gow A; Wu Y; Hirsch I; Goldman M; Newbold P; Zangrilli JG
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139780
[TBL] [Abstract][Full Text] [Related]
2. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience with benralizumab during 6 months.
Padilla-Galo A; Levy-Abitbol R; Olveira C; Valencia Azcona B; Pérez Morales M; Rivas-Ruiz F; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
BMC Pulm Med; 2020 Jun; 20(1):184. PubMed ID: 32600318
[TBL] [Abstract][Full Text] [Related]
5. Real-life cost-effectiveness of benralizumab in patients with severe asthma.
Padilla-Galo A; García-Ruiz AJ; Levy Abitbol RC; Olveira C; Rivas-Ruiz F; García-Agua Soler N; Pérez Morales M; Valencia Azcona B; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
Respir Res; 2021 May; 22(1):163. PubMed ID: 34044819
[TBL] [Abstract][Full Text] [Related]
6. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma.
Bleecker ER; Meyers DA; Billheimer D; Li H; Newbold P; Kwiatek J; Hirsch I; Katial R; Li X
J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1805-1813. PubMed ID: 36868471
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study).
Wedner HJ; Fujisawa T; Guilbert TW; Ikeda M; Mehta V; Tam JS; Lukka PB; Asimus S; Durżyński T; Johnston J; White WI; Shah M; Werkström V; Jison ML;
Pediatr Allergy Immunol; 2024 Mar; 35(3):e14092. PubMed ID: 38491795
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.
Lai K; Sun D; Dai R; Samoro R; Park HS; Åstrand A; Cohen D; Jison M; Shih VH; Werkström V; Yao Y; Zhang Y; Zheng W; Zhong N; ; ; Albert A; Jianping B; Bi C; Lijun C; Mei C; Min C; Ping C; Zhimin C; Chih-Feng C; Sook CY; Xiuhua F; Xiwen G; Wei G; Wei H; Zhihai H; Wei HX; Kewu H; Mao H; Grace Dawn IM; Inbeom J; Luning J; Mingyan J; Shanping J; Meiling J; Jian K; Woo KJ; Sang-Ha K; Jiulong K; Ping-Hung K; Jie L; Manxiang L; Minjing L; Ruoran L; Wen L; Xianhua L; Yanming L; Yong LS; Chuanhe L; Chuntao L; Jing L; Xiaoxia L; Huiyu L; Zhuang L; Shengxi M; Liangping M; Hoon MK; Lin M; Choon-Sik P; Sim PH; Hye-Kyung P; Jung-Won P; Diahn-Warng P; Ronnie S; Guochao S; Debin S; Dejun S; Chun-Hua W; Guangfa W; Limin W; Xuefen W; Yan W; Liping W; Haihong W; Yi X; Zuke X; Canmao X; Jin-Fu X; Xingxiang X; Xiyuan X; Jianping Y; Hongzhong Y; Joo YH; Wencheng Y; Jin Z; Longju Z; Min Z; Wei Z; Jianping Z; Ziwen Z; Xiaoli Z; Yingqun Z; ; ;
Respir Med; 2024 Apr; ():107611. PubMed ID: 38570145
[TBL] [Abstract][Full Text] [Related]
10. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R; Harrison TW; Chanez P; Menzella F; Philteos G; Cosio BG; Lugogo NL; de Luiz G; Burden A; Adlington T; Keeling N; Kwiatek J; Garcia Gil E;
J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1759-1770.e7. PubMed ID: 36948488
[TBL] [Abstract][Full Text] [Related]
11. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
[TBL] [Abstract][Full Text] [Related]
13. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness.
Li X; Newbold P; Katial R; Hirsch I; Li H; Martin UJ; Meyers DA; Bleecker ER
J Allergy Clin Immunol Pract; 2024 Apr; ():. PubMed ID: 38663470
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
15. Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma.
Smith JL; Chung Y; Barron J; Barlows T; Nepal B; Carstens D
J Asthma; 2024 Jun; 61(6):520-531. PubMed ID: 38054593
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
[TBL] [Abstract][Full Text] [Related]
17. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
[TBL] [Abstract][Full Text] [Related]
18. [The effectiveness of targeted therapy of various genetically engineered biological drugs in the treatment of bronchial asthma].
Shogenova MS; Hutueva SH; Shogenova LS
Ter Arkh; 2024 Jan; 95(12):1112-1118. PubMed ID: 38785050
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of benralizumab in elderly subjects with severe asthma.
Valverde-Monge M; Cárdenas R; García-Moguel I; Rosado A; Gandolfo-Cano M; Echarren TR; Moro-Moro MDM; Reaño Martos MDM; Pineda-Pineda R; Arroba CM; Domínguez-Ortega J;
J Asthma; 2024 Mar; 61(3):232-237. PubMed ID: 37737844
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
